^
Association details:
| Biomarker: | SPOP mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug Class: | Androgen receptor inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SPOP mutations as a Predictive Biomarker for Androgen Receptor-Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer
Published date:
09/11/2022
Excerpt:
In the ARAT cohort, presence of SPOP mutation compared to wild-type was associated with more favorable TTCRPC (not reached (NR) vs. 16.7 months, adjusted HR (aHR) 0.20; 95% CI 0.06-0.63; p=0.006) and OS (NR vs. 27.2 months, aHR 0.19; 95% CI 0.05-0.79; p=0.022).
DOI:
https://doi.org/10.1158/1078-0432.CCR-22-2228
